Xention

Develops ion channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder and chronic cough.

placeCambridge, England, United Kingdom calendar_todayFounded 2002 groups13 employees language xention.com

Registered entities

Investor mix

15 investors on record; lead investors include Seroba Life Sciences, BTG International.

Investor typeCountShare
Venture capital213%
Private equity427%
Bank & private debt17%
Other / undisclosed853%
Coming soon